Zhejiang Ausun Pharmaceutical Co Ltd (603229) — Net Asset Quality Index
Zhejiang Ausun Pharmaceutical Co Ltd (603229) has a Net Asset Quality Index of 75.0% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.16 Billion minus total liabilities of CN¥789.65 Million yields net assets of CN¥2.37 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read Zhejiang Ausun Pharmaceutical Co Ltd total liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Zhejiang Ausun Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2012–2025)
This chart shows how Zhejiang Ausun Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the index stands at 75.0%, representing net assets of CN¥2.37 Billion against total assets of CN¥3.16 Billion CNY. For live market cap and overall valuation, see market cap of Zhejiang Ausun Pharmaceutical Co Ltd.
Annual Net Asset Quality Index for Zhejiang Ausun Pharmaceutical Co Ltd (2012–2025)
The table below presents the year-by-year Net Asset Quality Index for Zhejiang Ausun Pharmaceutical Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check Zhejiang Ausun Pharmaceutical Co Ltd strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 73.6% | CN¥2.27 Billion | CN¥3.09 Billion | CN¥815.89 Million | ▼ -2.6 pp |
| 2024 | 76.2% | CN¥2.27 Billion | CN¥2.98 Billion | CN¥710.50 Million | ▲ +3.6 pp |
| 2023 | 72.6% | CN¥2.14 Billion | CN¥2.95 Billion | CN¥809.99 Million | ▲ +9.4 pp |
| 2022 | 63.1% | CN¥1.46 Billion | CN¥2.32 Billion | CN¥854.19 Million | ▼ -5.1 pp |
| 2021 | 68.2% | CN¥1.25 Billion | CN¥1.84 Billion | CN¥584.64 Million | ▼ -13.3 pp |
| 2020 | 81.6% | CN¥1.13 Billion | CN¥1.38 Billion | CN¥254.81 Million | ▲ +8.8 pp |
| 2019 | 72.8% | CN¥645.19 Million | CN¥886.14 Million | CN¥240.96 Million | ▼ -1.7 pp |
| 2018 | 74.5% | CN¥597.60 Million | CN¥801.98 Million | CN¥204.38 Million | ▼ -1.7 pp |
| 2017 | 76.2% | CN¥564.93 Million | CN¥741.58 Million | CN¥176.65 Million | ▲ +21.6 pp |
| 2016 | 54.5% | CN¥243.30 Million | CN¥446.06 Million | CN¥202.76 Million | ▲ +7.7 pp |
| 2015 | 46.8% | CN¥188.07 Million | CN¥401.89 Million | CN¥213.81 Million | ▲ +16.7 pp |
| 2014 | 30.1% | CN¥78.21 Million | CN¥260.11 Million | CN¥181.90 Million | ▲ +11.7 pp |
| 2013 | 18.4% | CN¥32.91 Million | CN¥178.78 Million | CN¥145.87 Million | ▲ +10.0 pp |
| 2012 | 8.4% | CN¥10.36 Million | CN¥122.57 Million | CN¥112.21 Million | — |